Cybin Inc reports results for the quarter ended March 31 - Earnings Summary

• Cybin Inc NEO:HELP reported a quarterly adjusted loss of C$1.17​​ per share for the quarter ended March 31, higher than the same quarter last year, when the company reported EPS of C$-1.46. The mean expectation of eight analysts for the quarter was for a loss of 93 cents per share. Wall Street expected results to range from C$-1.18 to -57 cents per share.

• Reported revenue was zero​; analysts expected zero.

• Cybin Inc's reported EPS for the quarter was a loss of C$1.17​.

• The company reported a quarterly loss of C$64.46 million.

• Cybin Inc shares had risen by 35.0% this quarter and lost 20.8% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 4.6% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

• Wall Street's median 12-month price target for Cybin Inc is $46.00, about 85.9% above its last closing price of $6.48

This summary was machine generated from LSEG data June 29 at 09:02 p.m. UTC. ​All figures in Canadian dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact )